Salem Investment Counselors’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $194K | Hold |
1,022
| – | – | ﹤0.01% | 413 |
|
|
2026
Q1 | $202K | Buy |
+1,022
| New | +$197K | 0.01% | 385 |
|
|
2025
Q4 | – | Sell |
-707
| Closed | -$108K | – | 455 |
|
|
2025
Q3 | $108K | Sell |
707
-64
| -8% | -$9.69K | ﹤0.01% | 454 |
|
|
2025
Q2 | $108K | Sell |
771
-13
| -2% | -$1.82K | ﹤0.01% | 450 |
|
|
2025
Q1 | $115K | Buy |
784
+15
| +2% | +$2.17K | ﹤0.01% | 430 |
|
|
2024
Q4 | $101K | Buy |
769
+63
| +9% | +$8.82K | ﹤0.01% | 456 |
|
|
2024
Q3 | $110K | Buy |
706
+18
| +3% | +$2.91K | ﹤0.01% | 443 |
|
|
2024
Q2 | $107K | Hold |
688
| – | – | ﹤0.01% | 433 |
|
|
2024
Q1 | $93.2K | Buy |
688
+7
| +1% | +$927 | ﹤0.01% | 460 |
|
|
2023
Q4 | $91.7K | Hold |
681
| – | – | ﹤0.01% | 455 |
|
|
2023
Q3 | $92.2K | Sell |
681
-753
| -53% | -$103K | ﹤0.01% | 428 |
|
|
2023
Q2 | $205K | Hold |
1,434
| – | – | 0.01% | 329 |
|
|
2023
Q1 | $199K | Sell |
1,434
-875
| -38% | -$118K | 0.01% | 337 |
|
|
2022
Q4 | $313K | Buy |
2,309
+877
| +61% | +$110K | 0.01% | 284 |
|
|
2022
Q3 | $157K | Sell |
1,432
-156
| -10% | -$19.8K | 0.01% | 334 |
|
|
2022
Q2 | $210K | Buy |
1,588
+168
| +12% | +$22K | 0.01% | 315 |
|
|
2022
Q1 | $188K | Hold |
1,420
| – | – | 0.01% | 346 |
|
|
2021
Q4 | $165K | Buy |
1,420
+920
| +184% | +$108K | 0.01% | 390 |
|
|
2021
Q3 | $60K | Hold |
500
| – | – | ﹤0.01% | 477 |
|
|
2021
Q2 | $60K | Hold |
500
| – | – | ﹤0.01% | 459 |
|
|
2021
Q1 | $50K | Sell |
500
-8
| -2% | -$804 | ﹤0.01% | 456 |
|
|
2020
Q4 | $51K | Buy |
508
+8
| +2% | +$847 | ﹤0.01% | 429 |
|
|
2020
Q3 | $55K | Hold |
500
| – | – | ﹤0.01% | 362 |
|
|
2020
Q2 | $53K | Hold |
500
| – | – | ﹤0.01% | 360 |
|
|
2020
Q1 | $45K | Hold |
500
| – | – | ﹤0.01% | 356 |
|
|
2019
Q4 | $50K | Hold |
500
| – | – | ﹤0.01% | 376 |
|
|
2019
Q3 | $45K | Hold |
500
| – | – | ﹤0.01% | 377 |
|
|
2019
Q2 | $41K | Sell |
500
-150
| -23% | -$11.8K | ﹤0.01% | 390 |
|
|
2019
Q1 | $51K | Buy |
+650
| New | +$51.2K | 0.01% | 287 |
|
|
2018
Q4 | – | Sell |
-650
| Closed | -$51K | – | 199 |
|
|
2018
Q3 | $51K | Hold |
650
| – | – | 0.01% | 287 |
|
|
2018
Q2 | $46K | Hold |
650
| – | – | ﹤0.01% | 297 |
|
|
2018
Q1 | $45K | Sell |
650
-350
| -35% | -$24.2K | 0.01% | 294 |
|
|
2017
Q4 | $69K | Hold |
1,000
| – | – | 0.01% | 280 |
|
|
2017
Q3 | $68K | Buy |
+1,000
| New | +$63.2K | 0.01% | 275 |
|
|
2017
Q2 | – | Sell |
-868
| Closed | -$107K | – | 661 |
|
|
2017
Q1 | $107K | Buy |
+868
| New | +$50.5K | 0.01% | 291 |
|
Other funds holding AZN
RG
SAM
CDDEC
MGP
Salem Investment Counselors's AZN Position: Q2 2026 in Review
Salem Investment Counselors held its AstraZeneca (AZN) position steady in Q2 2026 at 1,022 shares worth $194K. The position accounts for ﹤0.01% of the portfolio, ranked #413.
Salem Investment Counselors first reported a position in AZN in Q1 2017 and has held it in 35 quarters since. The position peaked at $313K in Q4 2022. 853 funds tracked by Wall St. Rank hold AZN as of Q2 2026.
- Salem Investment Counselors held 1,022 shares of AstraZeneca worth $194K as of Q2 2026.
- Salem Investment Counselors left its AstraZeneca share count unchanged in Q2 2026.
- AstraZeneca made up ﹤0.01% of Salem Investment Counselors's portfolio in Q2 2026, its #413 holding.
- Salem Investment Counselors first reported a position in AstraZeneca in Q1 2017 and has held it in 35 quarters since.
- Salem Investment Counselors's AstraZeneca position peaked at $313K in Q4 2022.
- 853 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.
Based on Salem Investment Counselors's 13F filing for Q2 2026, filed 14 Jul 2026.